Roth Capital Comments on Zevra Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at Roth Capital decreased their FY2024 earnings per share (EPS) estimates for Zevra Therapeutics in a research report issued on Tuesday, September 24th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of ($1.57) for the year, down from their prior forecast of ($1.49). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.59) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.32) EPS, FY2025 earnings at $0.09 EPS, FY2026 earnings at $1.20 EPS, FY2027 earnings at $2.36 EPS and FY2028 earnings at $2.28 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The firm had revenue of $4.45 million during the quarter, compared to analysts’ expectations of $4.08 million. Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. During the same quarter last year, the company posted ($0.15) earnings per share.

Several other brokerages also recently weighed in on ZVRA. HC Wainwright boosted their price target on Zevra Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Friday, September 20th. JMP Securities began coverage on Zevra Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $17.00 target price for the company. Canaccord Genuity Group decreased their price target on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Wednesday, September 18th. Roth Mkm upped their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Maxim Group increased their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA opened at $6.92 on Thursday. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $8.95. The firm has a 50 day simple moving average of $7.16 and a 200-day simple moving average of $5.76. The firm has a market cap of $364.13 million, a PE ratio of -5.13 and a beta of 1.94. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ZVRA. Armistice Capital LLC purchased a new position in shares of Zevra Therapeutics in the 4th quarter valued at $1,755,000. Sanctuary Advisors LLC purchased a new position in Zevra Therapeutics in the second quarter valued at about $474,000. Vanguard Group Inc. lifted its stake in shares of Zevra Therapeutics by 3.6% during the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after purchasing an additional 58,866 shares in the last quarter. Retirement Planning Co of New England Inc. lifted its stake in shares of Zevra Therapeutics by 11.0% during the first quarter. Retirement Planning Co of New England Inc. now owns 430,193 shares of the company’s stock worth $2,495,000 after purchasing an additional 42,766 shares in the last quarter. Finally, Mystic Asset Management Inc. boosted its position in shares of Zevra Therapeutics by 15.4% in the first quarter. Mystic Asset Management Inc. now owns 266,297 shares of the company’s stock worth $1,545,000 after buying an additional 35,514 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zevra Therapeutics

In other news, Director John B. Bode purchased 10,000 shares of the company’s stock in a transaction on Friday, July 12th. The stock was bought at an average cost of $5.87 per share, for a total transaction of $58,700.00. Following the completion of the purchase, the director now directly owns 30,000 shares of the company’s stock, valued at approximately $176,100. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have bought 22,000 shares of company stock worth $140,340. 2.40% of the stock is owned by insiders.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.